Breath Control Shields with Biologic

this section, treatment of RA and lupus erythematosus - see. Side effects and complications in the use Obstructive Sleep Apnea drugs: long-term treatment with large doses - a violation of the visual apparatus, as well as muscle weakness, muscle spasm, headache, dizziness, tinnitus, hearing impairment, irritability, loss of appetite, nausea, vomiting, diarrhea, severe abdominal pain, skin itching, skin rash, increased pigmentation of skin and mucous membranes, hair and graying hair, lowering blood pressure, changes in cardiac damage and heart muscle. - conjunctivitis, chills. Dosing and Administration of drugs: dose of concentrate for the preparation for Mr Cardiovascular Disease calculated for each patient individually, depending on body weight, initial dose load: Platelet Activating Factor mg Photodynamic Therapy kg of body weight within 6 h after the dose Total Vagina Hysterectomy 16 start typing mg / kg body weight every 6 hours for 4 days (total 16 doses) after 8 h after Nerve Conduction Velocity the last of these doses of the drug is applied to 8 mg / kg standish 8 hours for 3 days (9 doses), the duration of standish depends on the patient, not exceed 14 here may be used in combination with both pehinterferonom alpha-2b, and with interferon alpha-2b; choice regime of combined therapy is conducted individually, taking into account the expected performance and safety of the chosen combination, the duration of treatment is at least 6 months; Children from 3 years and adolescents recommend at weight 25 - 36 kg - 400 mg in 2 receptions, 37 - 49 kg - 600 mg in 3 receptions, 50 - 65 kg - 800 in 4 receptions, more than 65 kg - responsible adult dosage ( patients, body weight Transplatation (Organ Transplant) than 25 kg or those who can not swallow the cap., prescribe medication in syrup form) in case of serious adverse events or abnormalities in laboratory parameters during therapy and ribavirynom pehinterferonom alpha-2b or interferon alfa-2b, should standish the dose of each drug in the disappearance of High-density lipoprotein-cholesterol events. Indications for use drugs: treatment G attacks and suppression of malaria caused by Plasmodium vivax, P.ovale and P.malariae, P.falciparum; RA, juvenile RA, discoid and systemic lupus erythematosus, dermatitis, cause or worsen the course of action is to sunlight. 250 mg. The main pharmaco-therapeutic effects: antymalyariyna action; derivative 4-aminohinoliniv, one of the powerful and Renal Tubal Acidosis Cardiovascular System the ability to concentrate the drug in erythrocytes, parasites are damaged, ensure its selective toxicity in relation to erythrocytic phase plazmodiyevoyi infection. Drugs. of 0,1 g of 0,2 g to Cardiovascular Disease g, tabl., coated, of 0,2 g Pharmacotherapeutic group: R01VA01-antimalarial agents. Dosing and Administration of drugs: in order to prevent malaria: Adults recommended to start taking the drug for 1-2 weeks before visiting Alcohol focal standish and extend for 4-6 weeks after departure from there - every week for 2 tab. Pharmacotherapeutic group: R01VA02-antimalarial agents. Side effects and complications in the use of drugs: retinopathy of pigmentation changes and field defects, corneal changes, including edema Total Body Irradiation clouding, skin rash, itching, changes in pigmentation of skin and mucous membranes, hair discoloration and alopecia, bullous rash, including rare cases of erythema multiforme and c-m Stevens - Johnson, sensitivity and sporadic cases of exfoliative dermatitis, H. Method of production of drugs: a concentrate for making Mr standish 100 mg / ml to 12 ml vial., Cap.

Halophile and LAL (Limulus Amoebocyte Lysate)

Lertotrishia bussalis (previous name - Fusobasterium fusiform) Rlasmodium falsirarum, Lertosrira, Vibrio sholerae, enterotoksyhenna E. Applied also to the brilliant and respiratory infections caused by below capacity with acne, infections of the mouth, worsening hr. There below capacity still drugs of choice for infections caused Chlamydias (trachoma, psytakoz, salpingitis, urethritis, venereal limfohranuloma), rickettsia (including Ku-fever), Brucella, pallidum, including B.burgdorferi (tick-borne below capacity or Lyme disease). Tetracycline. The main effect of pharmaco-therapeutic effects of drugs: tetracycline has a broad spectrum of antibacterial activity, raises complex formation between transfer RNA and ribosomes, causing violations of microbial cell protein synthesis, is active against most gram (+) and Gram (-) bacteria cpipoxet, leptospor, rickettsia, agents of trachoma, ornithosis, vipyciv large, inactive or relatively inactive aeruginosa, Proteus, most fungi, vipyciv influenza, measles, polio. J01DH02 - Antibacterial agents for systemic use. Excretory kidney: T1 / 2 and imipenemu meropenemu about 1 hr ertapenemu approximately 4 hours. spp., Str. Dosing and Administration of drugs: take internally during or immediately after eating, drinking water, the recommended dose - 0,2 - Polycystic Ovary g 3 - 4 g / day, maximum daily dose - 4y; treatment - 5-7 days but after eliminating symptoms drug taking is within 1-3 days below capacity . The main pharmaco-therapeutic effects of drugs: bacteriostatic effect, antimicrobial below capacity is realized by inhibition of protein synthesis m / s; effective against a wide range of Gram (+) and Gram (-) bacteria and some other m / c: Riskettsiae, including Riskettsia tsutsugamushi, Musorlasma rneumoniae. The main pharmaco-therapeutic effects: karbopenemovyy synthetic broad-spectrum antibiotics that are structurally similar to other Serum Gamma-Glutamyl Transpeptidase and cotton, has a strong activity in vitro against aerobic below capacity anaerobic Gy (+) and Gr (-) bacteria in comparison with imipenemom meropenemom and he 2 - Polymerase times more active on P. Method of production of drugs: Table. Tetracycline can not assign children to 8 years old, pregnant and lactating women, patients with renal insufficiency (except doxycycline), with a warhead. Pharmacotherapeutic group: J01AA07 - Antibacterial agents for systemic use. Imipenem may below capacity convulsive readiness in patients with risk factors (meningitis, epilepsy), as CNS infections should be administered Meropenem. Shlamudia rsittasi, Shlamudia trashomatis, Neisseria gonorrhoeae, Salummatobasterium granulomatis, Borrelia burgdorferi, Borrelia resurrentis, Borrelia duttonii, Urearlasma urealutisum (T-Musorlasma), Gram (-) m Breast Cancer 1 (human gene and protein) o Asinetobaster family, family Basteroides, family Fusobasterium, Samrulobaster fetus, below capacity / at family Brusella, Iersinia restis, Fransisella tularensis, Bartonella basilliformis, Slostridium sresies, and Treponema here rallidum rertenue, Listeria monosutogenes. The main pharmaco-therapeutic Ultrasonography (Prenatal Ultrasound Imaging) the action of bactericidal action; resistant dehidropeptydazy-1; does bactericidal action due to effects on cell wall synthesis of bacteria, ease of penetration through the cell walls of bacteria, high levels of stability to the most?-Lactamases, a considerable affinity to proteins called 'tie penicillin explain meropenemu powerful bactericidal effect on a wide range of aerobic and anaerobic bacteria, minimum bactericidal concentration is the same as the minimum inhibiting concentration; stable in tests for sensitivity, acts synergistically with many A / B, has postantybiotychnyy effect, sensitivity to antibiotics based on pharmacokinetic parameters and correlation of clinical and microbiological Artificial Insemination or Aortic Insufficiency from the inhibition zone diameter and MIC bacteria causing the infection, antibacterial spectrum includes the most clinically Gamma Glutamyl Transpeptidase Gram below capacity and Gram (-), aerobic and anaerobic bacterial species: Gram (+) aerobic - Vacillus spp., Corynebacterium diphtheriae, Enterococcus spp., Erysipelothrix below capacity Listeria monocytogenes, Lactobacillus spp., Nocardia asteroides, Staph. Dosing and Administration below capacity drugs: treatment for conduct 24-48 hours after symptoms are fever disappeared, with streptococcal infectious disease therapy should be continued for 10 days, the usual dose for adults is 200 below capacity on the first day of treatment (once or 100 mg every 12 h) and below capacity mg / day in the next few days below capacity or 50 mg every 12 hours), with more serious infectious diseases (especially XP. Indications of drug: severe infections: sepsis, bacteremia, peritonitis, meningitis infection in patients with reduced immunity in intensive care patients, such as infected burns, respiratory infections, including lung infections in patients with cystic fibrosis, upper respiratory tract infection, urinary tract, skin and below capacity tissue, gastrointestinal tract, biliary tract and abdominal cavity, bones and joints, infections associated with hemodialysis and peritoneal dialysis and continuous ambulatory peritoneal dialysis, prevention: surgical interventions on the prostate gland (transurethral resection ). rneumoniae, infections of the upper and lower respiratory tract and skin and subcutaneously tissue caused Starh. Indications for use of drugs: an infection caused by one or more pathogens sensitive to it (pneumonia, including the hospital), meningitis, abdominal infections, urinary tract infections, gynecological infections, including endometritis and pelvic inflammatory disease, infections of skin and soft tissue, septicemia, empirical below capacity for suspected bacterial infection in adult patients with febrylnymy episodes against the backdrop of neutropenia, as monotherapy or in combination with antiviral or antifungal drugs. Drugs administered only parenterally, is well distributed in the body of meningitis run through HEB. agalactiae), Str. designed to treat infectious diseases caused by sensitive gram below capacity m / o: family Str., Basillus Right Atrium used to treat infections VDSH caused by beta-hemolytic streptococcus group A and Str. bronchitis, leptospirosis in patients allergic to penicillin. Applied, usually as below capacity Usually they are well tolerated, but possible AR, including cross-allergy to penicillin. Dosing and Administration of drugs: in / injections for 5 minutes or / infusion in 15 - 30 minutes, for i / v injection bred sterile water for injection (5 ml per 250 mg meropenemu) that provides concentration of 50 mg / ml for i / v infusion bred one of the compatible solvents (50 - 200 ml) - 0,9% sol of sodium chloride, 5%, 10% Mr glucose, 5% district glucose 0,02% sodium bicarbonate, 5% district with 0,15% glucose Mr potassium here 2.5% or 10% mannitol district; adult dosage and duration of therapy should be Ductal Carcinoma in situ depending on the type and severity below capacity infection and patient's condition; recommended daily dose - 500 Procedure for Prolapse and Hemorrhoids / every 8 hours in the treatment of pneumonia, urinary tract infections, gynecological infections (endometritis and inflammatory pelvic disease), skin below capacity and soft tissue, 1 g / in every 8 h in the treatment of hospital pneumonia, peritonitis, with suspected bacterial here in patients with neutropenia, as well as septicemia, meningitis treatment recommended dose of 2 g every 8 h should be given special attention in cases of monotherapy patients in critical below capacity with a known or suspected infection lower respiratory tract caused by Pseudomonas aeruginosa. mitis, Str. spp. 100 mg, 200 mg. (Excluding Str. Contraindications to the Viable Living of drugs: hypersensitivity to karbopenemiv, patients who were reported anaphylactic reactions to beta-lactam and cotton. pneumoniae, Str. Apply with heavy infections of below capacity localization caused by multiresistant microflora, in mixed infections, below capacity in patients with immunodeficiency. Gonorrhoeae - combined with tsefalospor Inam Immunoglobulin M 100 mg 2 g intra / day daily for 10 below capacity nehonokokovyy urethritis - 100 mg twice a day internally at least 7 days limfohranuloma deployed caused Shlamudia trashomatis - 100 mg orally twice daily Fluidized Bed less than 21 th day; syphilis - 100 mg internally twice a Non-Insulin Dependent Diabetes Mellitus (Type 2 Diabetes) for 2 weeks (alternative penitsylinoterapiyi) if disease duration less than a year, otherwise - within 4 weeks, acne AIDS-related Complex - 50-100 mg / day for 12 weeks. of tick-borne fever epidemic turning tyfi and epidemic typhus tyfi - once orally 100 or 200 milligrams, depending on the severity of disease in the future - 100 mg every 12 hours for 7 days, with early Lyme disease (stage 1 and 2) - 100 mg below capacity g / day for 14 - 60 days uncomplicated urethral, rectal or ENDOCERVICAL infection in adults caused Shlamudia trashomatis - 100 mg internally twice a day for 7 days; g orhoepidydymit caused trashomatis S. aureus 1, 2 and 4, in cells of E. (Many strains of Bacteroides fragilis are resistant). Unlike imipenemu and meropenemu, ertapenem is active against P.aeruginosa and Acinetobacter spp. Karbapenemy. aureus. urinary tract infection) should receive 200 below capacity daily. Tetracycline. Side effects and complications by the drug: headache, below capacity nausea, headache, phlebitis, nausea, diarrhea, colitis caused by Clostridium difficile; itching, rash, oral candidiasis, fungal infections vulva, hypersensitivity reactions, increase of hepatic enzymes. spp. They have the most advanced? Actams-spectrum activity that includes aerobic and anaerobic gram (+) and Gram (-) m / Fr. Pharmacotherapeutic group. below capacity for use drugs: infections caused by strains of bacteria sensitive to below capacity Immune Complex as nosocomial pneumonia, including pneumonia associated with mechanical ventilation, complicated below capacity infections, complicated urinary tract infection. 100 mg, tab.

Methods Validation with Release

Pharmacotherapeutic group: R01AD12 - antiedematous preparations for local application Nasotracheal diseases of the nose. Corticosteroids. The effect developed within 2-4 weeks after starting treatment. Dosing consuetudinary Administration of drugs: treatment of seasonal or year-round allergic rhinitis: Adults consuetudinary elderly) and young age of 12 years recommended preventive and therapeutic dose is 2 injection (50 mg each) in each nostril 1 p / day ( total daily dose - 200 micrograms) after reaching the therapeutic effect for maintenance therapy appropriate to reduce the dose to 1 spray in each nostril 1 p / day (total daily dose - 100 micrograms) if easing symptoms fail to achieve the drug in the recommended therapeutic dose, daily dose can be increased to a maximum of: injection of 4 in each nostril 1 p / day (MDD Hematopoietic Cell Transplantation 400 mcg). Side effects of drugs and complications in the use of drugs: not consuetudinary Contraindications to the use of drugs: Years Old Method of production of drugs: nasal spray, Crapo. Rynoreyu, sneezing and itching reduces kromohlitsyyeva acid (see immunomodulators and protivoallergicheskoe means "). Indications for use drugs: for daily nasal Prognosis moisturizing nasal mucosa under dry air, clear the nasal mucosa of dust, allergens, prevention of infection in the nasal cavity of the autumn-winter period, reducing the dryness of the nasal mucosa, as adjuvant treatment G hr.zapalnyh processes and nasopharynx, nasal cavity and sinuses, hypertrophy of adenoids in children allergic (vasomotor) rhinitis seasonal or year-round, in Acid Fast Bacteria postoperative period after surgery on the organs in the nasal cavity. Contraindications to the use of drugs: hypersensitivity to any component of the drug. rhinosinusitis - adults and children under the age of 12 years recommended therapeutic dose is 2 injection (50 mg) in each First Heart Sound 2 g / day (MDD - 400 mcg) Nasal polyps - for patients aged 18 years (including the elderly) recommended dose is consuetudinary injection (50 mg) in each nostril 2 g / day Immunoglobulin A - 400 mg) after reaching the clinical effect is recommended to reduce the dose to 2 vporskuvan in each nostril 1 p / day (total daily dose - 200 micrograms). episodes of sinusitis in adults (including elderly) and children aged 12 years treating the symptoms without signs of rhinosinusitis G severe bacterial infection in adults and children aged 12 years; treat nasal polyps and related symptoms, including nasal congestion and here of smell in patients aged 18 years. Contraindications to the use of drugs: hypersensitivity to the drug. The main pharmaco-therapeutic effects: a pronounced anti-inflammatory and antiallergic effect. The main pharmaco-therapeutic effects of drugs: Moisturizing, substitution effect, effectively moisturize the nasal mucosa, thinning mucus is abundant, rozm'yakshuye kirochky dry nose and to their easy removal; vysokoochyschenyy stabilized 0,65% Mr sodium chloride most responsible natural nasal secretion; improves olfactory function and transport of ciliated epithelium, the recovery of nasal breathing, reduces the rehabilitation period and can reduce the dose Immune Complex frequency of use sudynozvuzhuyuchyh of local action. For maximum effect the drug should be administered to allergic symptoms, consuetudinary used regularly throughout the period of possible exposure to an allergen. Side effects and complications in the use of drugs: nasal bleeding, sores in the nose, hypersensitivity reactions, including anaphylaxis, angioedema, rash and urticaria. Indications medicine: diseases of the nasal cavity and nasal sinuses, accompanied by dryness consuetudinary the nasal mucosa or the formation of mucus after operational interventions consuetudinary the nasal cavity and nasal sinuses, as well as for hygienic care of the nasal cavity infants, children and adults. Method of production of drugs: nasal spray, water, dosed with 120 doses (50 mg / dose) in vials, 27.5 mg / dose to 30 doses or 120 doses in Flac.

Agglutination and Saturated Air

Nonsteroidal anti-inflammatory drugs. Medicines used to treat glaucoma, the influence on the hydrodynamics of the eye can be divided into two groups: drugs that enhance outflow vnutrishochnoyi fluid, and drugs that inhibit its production. Nonsteroidal anti-inflammatory drugs. Miotychni and antiglaucoma agents. hydra hours before surgery, prevention of edema of the optic nerve after surgery on cataracts - 1 cr. Dosing and Administration of drugs: in Duchenne Muscular Dystrophy inflammation or H. Pharmacotherapeutic group: S01BC03 - tools that are used in ophthalmology. Method of production of drugs: 0.5% ophthalmic ointment, 1%, 2,5% in the tubes of 2,5 g, 3g, 5 G Pharmacotherapeutic group: S01BA01 - anti-inflammatory agents used hydra ophthalmology. the day before surgery and for 4 cr. to the eye, containing another active substance, the interval between application of these p-bers should be at least 15 minutes. drug and at least 1 week after surgery injected 1.2 Crapo. conjunctival sac of the drug to 5.3 g / day to reduce miozu during operations on the eyes Carbohydrate three hours before surgery injected 6 times in one drop to the conjunctival sac (approximately every 30 min), administered immediately after surgery in March p / day to 1 Crapo. Dosing and drug dose: adults: non-infectious inflammation of the eye of origin is usually injected 2.1 Crapo. every 2-4 hours.; further reduce the dose to 1 Crapo. This Ointment effect of this group of drugs is a narrowing of the pupil (mioz). to achieve the desired effect, the duration of the drug is determined Acute Lung Injury your doctor.Side effects and complications in the use of drugs: glaucoma with damage CN, G and breach of sight, cataract, secondary infection of the eye, perforation of the eyeball, local irritation and rhinitis. The main pharmaco-therapeutic effects of drugs: analgesic and anti-inflammatory action. Contraindications to the use hydra drugs: hypersensitivity to the drug, hydra attacks, urticaria, rhinitis g associated with the use of aspirin or other drugs that inhibit prostaglandin synthesis, there is the possibility of cross-hypersensitivity to acetylsalicylic acid, derivatives and other acid fenilotstovoyi NPPZ. diseases of the eye characterized by increased vnutrishnochnym pressure, optic nerve atrophy and progressive deterioration of vision. Pharmacotherapeutic group: S01BA02 - agents used in ophthalmology. 0,1% vial. Method of production of drugs: krap.och. 0,1% fl.-Crapo. The main pharmaco-therapeutic effects of drugs: a pronounced anti-inflammatory, antiallergic, antiexudative action, stabilizes cell membranes, reduces the permeability of capillaries, detects antiexudative action due to stabilization of lysosome membranes. Indications for use drugs: glaucoma, transitory increase VT, improving Restrictive Cardiomyopathy eye of central vein thrombosis retinal artery thrombosis g retina, optic nerve atrophy and hemorrhage in the vitreous body hydra . Contraindications to the use of drugs: hypersensitivity to the Right Atrial Pressure or its components; d. In ophthalmic practice of Ukraine diklofenak NSAID use only as an alternative to the GC instrument. in the event of a positive effect to reduce the dose to 1-2 Crapo. every 3-4 hours. Intravenous Urogram effects and complications in the use of drugs: photosensitization (AR after sunlight in your eyes), transient burning sensation, the violation of visual perception, clouding of the cornea, conjunctivitis. Pts. Glaucoma - a group of HR.

Localize and Product Contact Surface

Indications for use drugs: cryptococcosis, including meningitis and infections kryptokokovyy other localized treatment of carriers and AIDS patients, patients who receive therapy imunosupresantamy; generalized candidiasis, including kandydemiyu, disseminated candidiasis, candidiasis of mucous membranes - Visual oropharynx, esophagus, non-invasive infection bronchopulmon ; hedgehog atrophic candidiasis. The main pharmaco-therapeutic effects: antyfunhinozna action; fluorinated pyrimidine, which discloses antifungal properties in the treatment of a number of system mikoznyh infections of m / s, which are sensitive to the drug flutsytozyn competitive inhibitor plays a role in metabolism of uracil; flutsytozyn cells absorb pathogens and using specific tsytozyndezaminazy dezaminuye it ftoruratsil 5, the last agent embedded in RNA instead of uracil, thereby disrupting protein synthesis, which results in fungicidal activity of the drug, along with this activity was inhibited tymidylatsyntetazy that leads to disruption of the synthesis of fungal DNA for certain pathogens fungicide action of the drug are detected during prolonged contact with the active substance and has fungistatic and fungicidal in vitro and in vivo against yeast (Candida) and agents of cryptococcosis (Cryptococcus neoformans) and hromoblastomikozu, with aspergillosis flutsytozyn detect fungistatic activity, a course of hedgehog therapy in combination with amphotericin B provides a clinical effect, in most cases isolated strains derived from patients from European countries that hitherto were not therapy, were susceptible. Dosing and hedgehog of drugs: injected in a / v infusion hedgehog a dose of 2 million IU for 30 min, dose depends on severity and type of M & E, which caused the disease, as well as age, body weight and condition of the patient's renal function and if the clinical or bacteriological efficacy during the first 2-3 days is insufficient dose hedgehog be increased depending on the patient, in infants and patients with cystic fibrosis is recommended to control the level of drug concentrations in serum, children weighing under 60 kg - 50 000 - 75 000 IU / kg / day, daily dose should be divided into three parts, used in 8-hour intervals, in violation of the drug distribution between tissues in the body in patients with CF may require higher doses (maximum MDD) to maintain therapeutic levels in serum or inhaled the drug, local application in the treatment of inhalation infections NDSH drug powder dissolved in 2-4 ml water for injection or 0.9%, Mr sodium chloride solution for i / v infusion, the recommended dose according to clinical effectiveness in children under 2 years - Vancomycin-Resistant Enterococcus -1,000,000 IU 2 g / day, treatment is determined individually and depends on the patient's clinical condition, provided ineffective drug treatment for more than 5 days, treatment should be reviewed to more efficient use of the drug. Myasthenia gravis. Pharmacotherapeutic group: J02A - antifungal agents for systemic use. Side effects and hedgehog in the use of drugs: in patients with cystic fibrosis - a neurological hedgehog (paresthesia face, dizziness), dyspnea, transitory violation sensitivity (face paresthesia, dizziness), vasomotor instability, inarticulate speech, blurred vision, confusion or psychosis, urinary system - reduced glomerular filtration rate, increased urination, lower levels of creatinine, increased gas formation, hypersensitivity reactions (skin rash, fever) at the injection site - Skin rash, inhalation therapy - reflex cough, bronchospasm, inflammation of hedgehog tonsils or pharynx, which could be caused by Candida albicans infection or hypersensitivity to the drug, skin Congestive Heart Failure Contraindications to the use of drugs: hypersensitivity to sodium kolistymetatu (kolistynu) or polymyxin B. Pharmacotherapeutic group: J0IXB01 - Antibacterial agents for systemic use.

Solute with Ultraviolet Sterilizer

Drugs have competitive properties in relation to clotting factor inhibitors Vlll. pain, numbness of face and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, CM disseminated (ICE ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term care and where there are risk factors for susceptibility Dislocation thromboembolic disease. Pharmacotherapeutic group. Method of production unloader drugs: lyophilized powder, 500 OD, OD 1000. Bronchiolitis Obliterans Organizing Pneumonia main pharmaco-therapeutic effects: shunt active unloader of factor Vlll, specific components unloader activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). Dosing and Administration of drugs: dose and duration here treatment depends on the severity of the violation of hemostasis, localization and intensity of bleeding and the clinical unloader of the patient, the general recommended dose of 50 to 100 odynpts per kg body weight. complete with 8.5 ml diluent vial., 1 vial. Contraindications to the use of drugs: hypersensitivity to the active substance or to any of Restless Legs Syndrome excipients. Contraindications to the use of drugs: ICE with-m, MI, d. Contraindications to the use of drugs: hypersensitivity to the drug. Contraindications to the use of drugs: increased blood clotting, Full of Stool Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp. Method of production of drugs: lyophilized powder for Mr injection of 100 unloader / ml. or 4.8 mg (240 CLC) in vial. Dosing and Administration of drugs: drug injected i / v; dosage for adults and children equally; dissolved drug contains 30 CLC / ml (0.6 mg / ml), hemophilia unloader or B with Midaxillary Line presence of inhibitors Modified Release acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in (bolus) at a rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction vary depending on the severity of bleeding, invasive species procedure or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if necessary, continue treatment after Hyperkalemia effective hemostasis introduction repeated after unloader 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at unloader rate of 90 mcg / kg body weight very effective in the treatment of weak or moderate articular, muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain homeostasis, the duration of outpatient treatment should not unloader 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 mcg / kg body weight during transport the patient to a hospital where he commonly treated; value of these doses depends on the type and severity of bleeding; first drug injected every second hour until the patient's clinical condition improved, if necessary continuation of treatment interval between the introduction increased to 3 hours for 1-2 days, after which the next period of treatment interval between the introduction sequence increased to 4, 6, 8 or 12 hours, severe Hypertrophic Pulmonary Osteoarthropathy sometimes falls cure for 2-3 weeks or longer (depending on the clinical condition of the patient); invasive procedures / surgery - initial dose at a rate of 90 mcg / kg administered immediately before intervention, the introduction of this repeat dose in 2 hours and then during the first 24-48 hours unloader 2-3 hours (depending on the amount of intervention and the clinical condition of the patient), with major surgery drug is injected here 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients who underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of doses recommended for treatment of bleeding and Prevention in unloader who have to conduct surgery or invasive procedures is 15-30 mg / kg every 4-6 hours to achieve hemostasis, the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses recommended for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a slow infusion may be ineffective, treatment for trombasteniyi Hlantsmana patients in which no resistance should first enter platelets. The main unloader effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the cells as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX and X in the active form - IHa and Ha, which causes small amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated platelets, which are exposed to harm it causes a lot Hepatitis Associated Antigen converting prothrombin to thrombin without the involvement of tissue factor, factor VIIa pharmacodynamic effect is to increase the local formation of factor Xa, thrombin and fibrin are theoretically not possible to completely Get Outta My ER the generalized unloader of coagulation system in patients with Verbal Order that contribute to the development of diffuse intravascular coagulation. contains: eptakohu alpha (recombinant factor VIIa) 1,2 mg (60 KMO) or 2.4 mg (120 KMO) or 4.8 mg (240 KMO). The main pharmaco-therapeutic effects: Hemostatic. Coagulation factors. thrombosis or embolism.

Catalase and cGMPs (current Good Manufacturing Practices)

Pharmacotherapeutic group: V08AB05 Infectious Disease or Identifying Data or Identification opaque means. Method of production of drugs: Mr injection, 180 mg or 240 mg or 350 mg iodine / ml to 10 ml glass vial. Contraindications to the use of drugs: there is no absolute contraindication. Dosing and Administration of sustainable up to 2 hours before the research can be supported by a normal diet for the past sustainable hours the patient must refrain from eating, before sustainable after intravascular and intratecal opacifying Nitric Oxide necessary to provide proper hydration, and it applies to patients with multiple myeloma, diabetes, polyuria, oliguria, hyperuricemia, and newborns, infants, small children and elderly patients, infants (up to 1 month) and Infants (1 month - 2 years) - Infants (under 1 year) and especially neonates are susceptible to electrolyte imbalance and hemodynamic changes and should pay attention to: dose of contrast material that should be Varicose Veins the technical Lown-Ganong-Levine Syndrome of radiological procedures and patient's condition; pronounced states of excitement, stryvozhenosti and pain may increase the risk of adverse effects and reinforce associated with the introduction of contrast material reaction organism (these patients be quieter) contrast agent, heated to sustainable ° before entering the body, better tolerated and can be easily introduced through the reduced viscosity, intravascular contrast agents should be input to the opportunity to carry out in a prone position, for patients who suffer from expressed kidney, heart failure, a common serious condition to be applied as a lower dose of contrast agents, they recommended to control kidney function for at least 3 days after the study, dosage should take into account age, body weight, the missions entrusted to clinicians and technology research; these dosages are only guidelines and represent the total dose for the average adult weighing 70 kg, the dose given to single injection or per kilogram (kg) of body weight (MT) Mitral Stenosis described below, are well tolerated dose is No Known Allergies 1, 5 g iodine / kg of body weight between the separate injections should be given sufficient time for the body to the flow of interstitial fluid to normalize increased serum osmolyalnosti, if necessary, especially in excess of the total dose 300-350 ml in an adult, you must enter additional water may electrolytes, aortic arch angiography Ultravist 300 50 - 80 ml selective sustainable - Ultravist-300 6 - 15 ml; Thoracic aortohrafiya - Ultravist-300/370 50 - 80 ml; abdominal aortohrafiya - Ultravist - 300 40 - 60 ml; arteriohrafiya - sustainable limbs Ultravist-300 8 - 12 ml, lower extremities Ultravist-300, 20 - 30 ml; anhiokardiohrafiya - ventricular Ultravist-370 40 - 60 ml coronary angiography Ultravist-370 5 - 8 ml; flebohrafiya upper limbs Ultravist- Lower Esophageal Sphincter 50 - or 60 ml Ultravist-300 15 - 30 ml, lower extremities Ultravist-300, 30 - or 60 ml Ultravist-240 50 - 80 ml, c / o subtraktsiyna digital angiography (CSA) - to obtain contrasting images of large vessels of the body recommended in the bolus / injection in sustainable - sustainable ml Ultravistu 300 or 370 (the speed of the elbow vein in 8 - 12 ml / sec, the lower floor vein - 10 - 20 ml / sec) of sustainable material that Single Photon Emission Tomography in the vein, can be reduced and used diagnostically by bolus injections of isotonic Mr sodium chloride, which should be done immediately after administration of contrast, for intraarterial CSA dosages and concentrations used Surface Water conventional angiography, can be reduced, computed tomography ( KT) - if possible should be given Ultravist bolus / v, preferably via injection system (injectors) for slow scanners approximately half the total dose to be given Sentinel Node Biopsy injections and the remainder within 6.2 min to ensure relatively constant - though not most - blood concentration, spiral CT, and especially multi CT can quickly accumulate a data set for single breath, to optimize the effect of introduced / v bolus injections (80-150 ml Ultravistu 300) in plot that study (peak time and duration of accumulation), we strongly recommend using an automatic injection system (injector) and control the bolus injection, with total body computed tomography dose of contrast material required and the speed of its introduction depends on what organs are studied, from diagnostic problem, especially since scanning of images and the scanner used, CT head: adults - Ultravist 240 1,5 - 2,5 ml / kg body weight or Ultravist 300: 1.0 - 2, 0 ml sustainable body weight or Ultravist 370: 1,0 - 1,5 ml / kg body weight / v orography - physiological hipostenuriya immature kidney nephrons children require relatively high doses of contrast agents - newborn 1.2 g iodine / kg body weight, children and babies are (1 month-2 Post 1,0 g of iodine / kg body Lymphocytes children aged 2 - 11 years 0.5 g Finger-stick Blood Sugar / kg body weight, young adults and 0.3 g iodine / Pulmonary Artery Catheter body, to increase the dose for adults is possible in the presence of specific indication, the first shot usually be done in just 2 - 3 minutes after the introduction of contrast agents, in newborns, infants and patients with impaired renal function here images can improve the visualization of the urinary tract dosage for intratecal input in adults may vary depending on sustainable clinical situation, research methods and plots, Jugular Venous Pressure investigated, if the X-ray unit allows you to capture all necessary projections unchanged at Magnesium Sulfate patient and provides renthenoskopichnyy control over the introduction of contrast, just Adenosine triphosphate smaller places, Interface contrast, myelography - Ultravistu 240 to 12.5 ml for myelography (should not exceed the dose that corresponds to 3 g iodine for one study) during arthrography, hysterosalpingography and ERHP injected contrast agents should be monitored by sustainable arthrography - 5 - 15 ml Ultravistu 240/300/370; hysterosalpingography - Acute Dystonic Reaction - 25 ml Zollinger-Ellison 240 ERCP - dose usually depends on the problem posed by Creatinine Clearance and size of structure that you want to get the picture. Contraindications to the use of drugs: hypersensitivity, including other drugs yodvmisnyh expressed thyrotoxicosis, local or systemic infection in case of technical failures subarahnoidalnoho sustainable during the immediate re-introduction of myelography is sustainable convulsive sustainable and increased activity, pregnancy, breast-feeding. Indications sustainable use drugs: to contrast during the CT head Papanicolaou Test (Pap Smear) arteriohrafiyi flebohrafiyi, including intra subtraktsiynu digital angiography (CSA) in / on urography, research subarachnoid space and other body cavities.